263 related articles for article (PubMed ID: 28180075)
1. Independent value added by diffusion MRI for prediction of cognitive function in older adults.
Scott JA; Tosun D; Braskie MN; Maillard P; Thompson PM; Weiner M; DeCarli C; Carmichael OT;
Neuroimage Clin; 2017; 14():166-173. PubMed ID: 28180075
[TBL] [Abstract][Full Text] [Related]
2. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.
van Loenhoud AC; van der Flier WM; Wink AM; Dicks E; Groot C; Twisk J; Barkhof F; Scheltens P; Ossenkoppele R;
Neurology; 2019 Jul; 93(4):e334-e346. PubMed ID: 31266904
[TBL] [Abstract][Full Text] [Related]
3. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment.
Ten Kate M; Barkhof F; Visser PJ; Teunissen CE; Scheltens P; van der Flier WM; Tijms BM
Alzheimers Res Ther; 2017 Sep; 9(1):73. PubMed ID: 28899429
[TBL] [Abstract][Full Text] [Related]
4. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
Araque Caballero MÁ; Klöppel S; Dichgans M; Ewers M;
J Alzheimers Dis; 2017; 55(1):343-358. PubMed ID: 27662291
[TBL] [Abstract][Full Text] [Related]
5. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
[TBL] [Abstract][Full Text] [Related]
6. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.
Kandel BM; Avants BB; Gee JC; Arnold SE; Wolk DA;
J Alzheimers Dis; 2015; 46(4):901-12. PubMed ID: 25881908
[TBL] [Abstract][Full Text] [Related]
7. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
[TBL] [Abstract][Full Text] [Related]
8. Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study.
Wang YL; Chen W; Cai WJ; Hu H; Xu W; Wang ZT; Cao XP; Tan L; Yu JT;
J Alzheimers Dis; 2020; 73(2):759-768. PubMed ID: 31839612
[TBL] [Abstract][Full Text] [Related]
9. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment.
Schmand B; Eikelenboom P; van Gool WA;
J Alzheimers Dis; 2012; 29(3):641-8. PubMed ID: 22297644
[TBL] [Abstract][Full Text] [Related]
10. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.
Risacher SL; McDonald BC; Tallman EF; West JD; Farlow MR; Unverzagt FW; Gao S; Boustani M; Crane PK; Petersen RC; Jack CR; Jagust WJ; Aisen PS; Weiner MW; Saykin AJ;
JAMA Neurol; 2016 Jun; 73(6):721-32. PubMed ID: 27088965
[TBL] [Abstract][Full Text] [Related]
11. Associations of Vascular Risk with Cognition, Brain Glucose Metabolism, and Clinical Progression in Cognitively Intact Elders.
Yu GX; Zhang T; Hou XH; Ou YN; Hu H; Wang ZT; Guo Y; Xu W; Tan L; Yu JT; Tan L;
J Alzheimers Dis; 2021; 80(1):321-330. PubMed ID: 33523005
[TBL] [Abstract][Full Text] [Related]
12. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
[TBL] [Abstract][Full Text] [Related]
13. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort.
Dufouil C; Dubois B; Vellas B; Pasquier F; Blanc F; Hugon J; Hanon O; Dartigues JF; Harston S; Gabelle A; Ceccaldi M; Beauchet O; Krolak-Salmon P; David R; Rouaud O; Godefroy O; Belin C; Rouch I; Auguste N; Wallon D; Benetos A; Pariente J; Paccalin M; Moreaud O; Hommet C; Sellal F; Boutoleau-Bretonniére C; Jalenques I; Gentric A; Vandel P; Azouani C; Fillon L; Fischer C; Savarieau H; Operto G; Bertin H; Chupin M; Bouteloup V; Habert MO; Mangin JF; Chêne G;
Alzheimers Res Ther; 2017 Aug; 9(1):67. PubMed ID: 28851447
[TBL] [Abstract][Full Text] [Related]
14. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment.
Selnes P; Aarsland D; Bjørnerud A; Gjerstad L; Wallin A; Hessen E; Reinvang I; Grambaite R; Auning E; Kjærvik VK; Due-Tønnessen P; Stenset V; Fladby T
J Alzheimers Dis; 2013; 33(3):723-36. PubMed ID: 23186987
[TBL] [Abstract][Full Text] [Related]
15. White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration.
Kantarci K; Schwarz CG; Reid RI; Przybelski SA; Lesnick TG; Zuk SM; Senjem ML; Gunter JL; Lowe V; Machulda MM; Knopman DS; Petersen RC; Jack CR
JAMA Neurol; 2014 Dec; 71(12):1547-54. PubMed ID: 25347157
[TBL] [Abstract][Full Text] [Related]
16. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
17. Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.
Insel PS; Mattsson N; Mackin RS; Schöll M; Nosheny RL; Tosun D; Donohue MC; Aisen PS; Jagust WJ; Weiner MW;
Neurology; 2016 May; 86(20):1887-96. PubMed ID: 27164667
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
[TBL] [Abstract][Full Text] [Related]
19. Sex differences in the association between AD biomarkers and cognitive decline.
Koran MEI; Wagener M; Hohman TJ;
Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008
[TBL] [Abstract][Full Text] [Related]
20. Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline.
Torosyan N; Mason K; Dahlbom M; Silverman DHS;
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1355-1363. PubMed ID: 28331953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
